Seagen, A Wholly Owned Subsidiary Of Pfizer
Clinical trials sponsored by Seagen, A Wholly Owned Subsidiary Of Pfizer, explained in plain language.
-
Experimental cancer drug trial halted early
Disease control TerminatedThis study tested a new drug called PF-08046052/SGN-EGFRd2 in people with advanced solid tumors that could not be removed or had spread. The goal was to find a safe dose and check for side effects. The trial was terminated early, and it included people with colorectal, lung, head…
Phase: PHASE1 • Sponsor: Seagen, a wholly owned subsidiary of Pfizer • Aim: Disease control
Last updated Jun 22, 2026 12:06 UTC
-
New lymphoma drug trial halted early
Disease control TerminatedThis study tested a new drug, PF-08046045, in 22 adults with advanced lymphomas (cancers of the immune system). The goal was to find a safe dose and check for side effects. The trial was stopped early, so results are limited.
Phase: PHASE1 • Sponsor: Seagen, a wholly owned subsidiary of Pfizer • Aim: Disease control
Last updated Jun 18, 2026 11:48 UTC
-
New hope for advanced cervical cancer: targeted drug combo shows promise
Disease control TerminatedThis trial tested a drug called tisotumab vedotin, alone or with other medicines, in people with cervical cancer that had come back or spread. The study included 214 participants and aimed to find the best dose and see if the tumors shrank. The trial was stopped early, but the re…
Phase: PHASE1, PHASE2 • Sponsor: Seagen, a wholly owned subsidiary of Pfizer • Aim: Disease control
Last updated Jun 18, 2026 11:47 UTC
-
New cancer drug trial halted early – what we know
Disease control TerminatedThis study tested a new drug, felmetatug vedotin, alone or with pembrolizumab, in people with advanced solid tumors like ovarian, breast, and lung cancer. The goal was to check safety and find the right dose. The trial was terminated early, so results are limited.
Phase: PHASE1 • Sponsor: Seagen, a wholly owned subsidiary of Pfizer • Aim: Disease control
Last updated Jun 15, 2026 18:55 UTC
-
New lymphoma drug trial halted early
Disease control TerminatedThis early-stage study tested a new drug, PF-08046044/SGN-35C, in people with advanced lymphomas (Hodgkin and non-Hodgkin types) who had no other treatment options. The main goal was to check safety and find the right dose. The study was terminated early, so results are limited.
Phase: PHASE1 • Sponsor: Seagen, a wholly owned subsidiary of Pfizer • Aim: Disease control
Last updated Jun 10, 2026 13:26 UTC